Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) shares fell 8.6% on Thursday . The company traded as low as $2.01 and last traded at $2.13, with a volume of 51,324 shares. The stock had previously closed at $2.33.

A number of brokerages have weighed in on EYEG. Rodman & Renshaw reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a research note on Thursday, May 12th. Maxim Group reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a research note on Tuesday, April 26th. Chardan Capital reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a research note on Thursday, April 14th. Finally, Noble Financial began coverage on Eyegate Pharmaceuticals in a research note on Thursday, April 7th. They set a “buy” rating and a $10.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Eyegate Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $9.00.

The firm has a 50-day moving average of $2.67 and a 200 day moving average of $2.98. The stock’s market cap is $17.78 million.

In related news, major shareholder Ventech Capital Ii sold 28,600 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $3.04, for a total transaction of $86,944.00. Following the sale, the insider now owns 1,608,973 shares of the company’s stock, valued at $4,891,277.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Morton Goldberg sold 10,939 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $3.31, for a total value of $36,208.09. Following the sale, the director now directly owns 43,216 shares in the company, valued at approximately $143,044.96. The disclosure for this sale can be found here.

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.